1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017


Delayed Xetra  -  11:43 2022-06-30 am EDT
56.72 EUR   -1.56%
02:59aBayer's Finerenone Gets Chinese Nod for Treatment of Chronic Kidney Disease in Adults
02:32aBAYER : Kerendia™ (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
06/29Bayer Opens New $140 Million Oncology Research Facility in US
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis wins U.S. approval for targeted cancer drug combination

06/23/2022 | 05:25am EDT
FILE PHOTO: The Novartis logo is seen on the Swiss drugmaker's factory in Stein

FRANKFURT (Reuters) - A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumour agnostic.

The Food and Drug Administration early on Thursday granted accelerated approval for the combination of the two drugs Tafinlar and Mekinist for adults and children as young as six with inoperable or metastatic solid tumours with a mutation known as BRAF V600, who have exhausted other treatment options.

The approval may be changed or withdrawn, depending on the results of later confirmatory trials, the Swiss drugmaker said in a statement.

Earlier this month, the oral drug combination showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

The participants in that trial, aged 1 to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer. Here too, the trial only included those who were found to have the BRAF V600 mutation, a genetic contributor in about 15% to 20% of pediatric LGG cases.

Tafinlar and Mekinist, a pill combination with $1.7 billion in 2021 sales, up 10%, had previously won approvals to treat certain skin, lung and thyroid cancer patients who have the BRAF V600 genetic change.

The treatment is an important growth driver in Novartis's oncology business, a key therapeutic area for the Swiss group, which relies on drug development as it considers the sale of its Sandoz business with off-patent generic drugs.

Other tumour agnostic drugs, which are typically used on solid tumours regardless of where in the body they started, are Bayer's Vitrakvi and Roche's Rozlytrek, which target the TRK mutation, a genetic driver in less than 1% of cancers. Due to its rarity it often goes untested.

Bayer has said it was struggling to encourage physicians to diagnose patients that qualify for the niche drug.

(Reporting by Ludwig Burger. Editing by Jane Merriman)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -1.56% 56.72 Delayed Quote.20.68%
NOVARTIS AG -0.42% 80.85 Delayed Quote.1.13%
ROCHE HOLDING AG -0.34% 318.55 Delayed Quote.-15.68%
All news about BAYER AG
02:59aBayer's Finerenone Gets Chinese Nod for Treatment of Chronic Kidney Disease in Adults
02:32aBAYER : Kerendia™ (finerenone) approved in China for the treatment of adults with ch..
06/29Bayer Opens New $140 Million Oncology Research Facility in US
06/29BAYER : opens new Research & Innovation Center in Boston-Cambridge demonstrating its commi..
06/29Bayer AG Opens New Research & Innovation Center in Boston-Cambridge Demonstrating Its C..
06/28BAYER : expands Radiology Business into AI Market with Calantic™ Digital Solutions
06/27Bayer Gets US Supreme Court Rejection Anew for Roundup Weedkiller Case
06/27U.S. Supreme Court again nixes Bayer challenge to weedkiller suits
06/24BAYER AG : Berenberg reiterates its Buy rating
More news
Analyst Recommendations on BAYER AG
More recommendations
Sales 2022 48 518 M 50 719 M 50 719 M
Net income 2022 4 836 M 5 055 M 5 055 M
Net Debt 2022 33 111 M 34 613 M 34 613 M
P/E ratio 2022 11,7x
Yield 2022 3,89%
Capitalization 55 723 M 58 251 M 58 251 M
EV / Sales 2022 1,83x
EV / Sales 2023 1,75x
Nbr of Employees 100 753
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 56,72 €
Average target price 79,37 €
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG22.60%59 268
JOHNSON & JOHNSON3.43%465 732
PFIZER, INC.-14.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.84%272 382